3. Summary
Global Markets Direct’s, Age Related Macular Degeneration - Pipeline Review,
H2 2012, provides an overview of the indication’s therapeutic pipeline. This
report provides information on the therapeutic development for Age Related
Macular Degeneration, complete with latest updates, and special features on
late-stage and discontinued projects. It also reviews key players involved in the
therapeutic development for Age Related Macular Degeneration. Age Related
Macular Degeneration - Pipeline Review, Half Year is built using data and
information sourced from Global Markets Direct’s proprietary databases,
Company/University websites, SEC filings, investor presentations and featured
press releases from company/university sites and industry-specific third party
sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
4. Scope
- A snapshot of the global therapeutic scenario for Age Related Macular
Degeneration.
- A review of the Age Related Macular Degeneration products under development by
companies and universities/research institutes based on information derived from
company and industry-specific sources.
- Coverage of products based on various stages of development ranging from
discovery till registration stages.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under
development for Age Related Macular Degeneration.
- Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage.
5. Table of Contents :
List of Tables 8
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Age Related Macular Degeneration Overview 13
Therapeutics Development 14
An Overview of Pipeline Products for Age Related Macular Degeneration 14
Age Related Macular Degeneration Therapeutics under Development by
Companies 16
Age Related Macular Degeneration Therapeutics under Investigation by
Universities/Institutes 24
Late Stage Products 27
Comparative Analysis 27
Mid Clinical Stage Products 28
Comparative Analysis 28
Early Clinical Stage Products 29
Comparative Analysis 29
Discovery and Pre-Clinical Stage Products 30
Comparative Analysis 30………………
6. Please follow link if you want More Related
Reports :
Pipeline Review, H2 2012
http://www.aarkstore.com/search/viewresults.asp?searc
h=Pipeline Review, H2 2012&PubId=&pagenum=1